Category
June 3, 2016
The Cancer Prevention & Research Institute of Texas has awarded nearly $11 million to the University of Texas Health Science Center at San Antonio in its latest funding round. That award includes $5 million to help establish the Texas Pediatric Patient-Derived Xenograft Facility. Peter Houghton, director of the Greehey Children’s Cancer Research Institute at the […]
May 20, 2016
The Greehey Children’s Cancer Research Institute at the Health Science Center garnered $10.9 million from the Cancer Prevention & Research Institute of Texas (CPRIT)―a larger amount than any other academic institution in the state. The Health Science Center received 24 percent of the $45.3 million awarded to 13 academic institutions on May 18. The grant was the […]
May 20, 2016
The Greehey Children’s Cancer Research Institute at the Health Science Center garnered $10.9 million from the Cancer Prevention & Research Institute of Texas (CPRIT)―a larger amount than any other academic institution in the state. The Health Science Center received 24 percent of the $45.3 million awarded to 13 academic institutions on May 18. The grant was the […]
May 18, 2016
Raushan T. Kurmasheva & Peter J. Houghton Abstract In the USA, the overall cure rate for all childhood cancers is seventy percent, and in many patients that ultimately fail curative therapy, initial responses to current multimodality treatments (surgery, radiation therapy, and chemotherapy) are good, with overall 5-year event-free survival approaching 80 %. However, current approaches to curative […]
May 15, 2016
Hemant K Bid 1, Doris A Phelps 1, Linlin Xaio 1, Denis C Guttridge 2, Jiayuh Lin 1, Cheryl London 3, Laurence H Baker 4, Xiaokui Mo 5, Peter J Houghton 6 Abstract The bromodomain and extra-terminal domain inhibitor JQ1 has marked antitumor activity against several hematologic malignancies as well as solid tumor models. Here, we investigated its activity in vitro and in vivo against models of childhood rhabdomyosarcoma and Ewing sarcoma. […]
May 1, 2016
Abstract Aging is the strongest known risk factor for Alzheimer’s disease (AD). With the discovery of the mechanistic target of rapamycin (mTOR) as a critical pathway controlling the rate of aging in mice, molecules at the interface between the regulation of aging and the mechanisms of specific age-associated diseases can be identified. We will review […]
May 1, 2016
Rodrigo A. Toledo, Yuejuan Qin, Zi-Ming Cheng, Qing Gao, Shintaro Iwata, Gustavo M. Silva, Manju L. Prasad, I. Tolgay Ocal, Sarika Rao, Neil Aronin, Marta Barontini, Jan Bruder, Robert L. Reddick, Yidong Chen, Ricardo C.T. Aguiar and Patricia L.M. Dahia Abstract Purpose: Pheochromocytomas and paragangliomas (PPGL) are genetically heterogeneous tumors of neural crest origin, but the molecular basis of most PPGLs is unknown. Experimental Design: We performed exome or transcriptome sequencing of 43 samples from 41 patients. A validation set of 136 PPGLs was used for amplicon-specific resequencing. In […]
April 21, 2016
Alfeu Zanotto-Filho, Ravi Dashnamoorthy, Eva Loranc, Luis H. T. de Souza, José C. F. Moreira, Uthra Suresh, Yidong Chen, Alexander J. R. Bishop Abstract Alkylating agents are a key component of cancer chemotherapy. Several cellular mechanisms are known to be important for its survival, particularly DNA repair and xenobiotic detoxification, yet genomic screens indicate that […]
April 21, 2016
Alfeu Zanotto-Filho, Ravi Dashnamoorthy, Eva Loranc, Luis H. T. de Souza, José C. F. Moreira, Uthra Suresh, Yidong Chen, Alexander J. R. Bishop Abstract Alkylating agents are a key component of cancer chemotherapy. Several cellular mechanisms are known to be important for its survival, particularly DNA repair and xenobiotic detoxification, yet genomic screens indicate that […]
April 17, 2016
Michelle L. Churchman,1 Kathryn Evans,2 Jennifer Richmond,2 Alissa Robbins,2 Luke Jones,2 Irina M. Shapiro,3 Jonathan A. Pachter,3 David T. Weaver,3 Peter J. Houghton,4 Malcolm A. Smith,5 Richard B. Lock,2 and Charles G. Mullighan1 Abstract BCR-ABL1+ B progenitor acute lymphoblastic leukemia (Ph+ B-ALL) is an aggressive disease that frequently responds poorly to currently available therapies. Alterations in IKZF1, which encodes the lymphoid transcription factor Ikaros, are present in over 80% of […]